International Journal of Clinical Case Reports 2024, Vol.14, No.3, 132-143 http://medscipublisher.com/index.php/ijccr 142 Adotévi O., Vernerey D., Jacoulet P., Meurisse A., Laheurte C., Almotlak H., Jacquin M., Kaulek V., Boullerot L., Malfroy M., Orillard E., Eberst G., Lagrange A., Favier L., Gainet-Brun M., Doucet L., Teixeira L., Ghrieb Z., Clairet A., Guillaume Y., Kroemer M., Hocquet D., Moltenis M., Limat S., Quoix E., Mascaux C., Debieuvre D., Fagnoni-Legat C., Borg C., and Westeel V., 2022, Safety immunogenicity and 1-year efficacy of universal cancer peptide-based vaccine in patients with refractory advanced non-small-cell lung cancer: a phase Ib/Phase IIa De-escalation study, Journal of Clinical Oncology, 41: 373-384. https://doi.org/10.1200/JCO.22.00096 PMid:36070539 Bezu L., Kepp O., Cerrato G., Pol J., Fucikova J., Spí ek R., Zitvogel L., Kroemer G., and Galluzzi L., 2018, Trial watch: peptide-based vaccines in anticancer therapy, Oncoimmunology, 7(12): e1511506. https://doi.org/10.1080/2162402X.2018.1511506 Brinkman J., Fausch S., Weber J., and Kast W., 2004, Peptide-based vaccines for cancer immunotherapy, Expert Opinion on Biological Therapy, 4: 181-198. https://doi.org/10.1517/14712598.4.2.181 PMid:14998777 Buonaguro L., and Tagliamonte M., 2023, Peptide-based vaccine for cancer therapies, Frontiers in Immunology, 14: 1210044. https://doi.org/10.3389/fimmu.2023.1210044 PMid:37654484 PMCid:PMC10467431 Daiko H., Marafioti T., Fujiwara T., Shirakawa Y., Nakatsura T., Kato K., Puccio I., Hikichi T., Yoshimura S., Nakagawa T., Furukawa M., Stoeber K., Nagira M., Ide N., and Kojima T., 2020, Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients, Cancer Immunology Immunotherapy, 69: 2247-2257. https://doi.org/10.1007/s00262-020-02619-3 Gallou C., Rougeot A., Graff-Dubois S., Kosmatopoulos K., and Menez-Jamet J., 2016, A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients, Oncotarget, 7: 59417-59428. https://doi.org/10.18632/oncotarget.11086 Hamley I., 2022, Peptides for vaccine development, ACS Applied Bio Materials, 5: 905-944. https://doi.org/10.1021/acsabm.1c01238 PMid:35195008 PMCid:PMC9384901 Hazama S., Nakamura Y., Takenouchi H., Suzuki N., Tsunedomi R., Inoue Y., Tokuhisa Y., Iizuka N., Yoshino S., Takeda K., Shinozaki H., Kamiya A., Furukawa H., and Oka M., 2014, A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety immunological response and clinical outcome, Journal of Translational Medicine, 12: 63-63. https://doi.org/10.1186/1479-5876-12-63. He X., Abrams S., and Lovell J., 2018, Peptide delivery systems for cancer vaccines, Advanced Therapeutics, 5(1): 1800060. https://doi.org/10.1002/adtp.201800060. Hirayama M., and Nishimura Y., 2016, The present status and future prospects of peptide-based cancer vaccines., International Immunology, 28(7): 319-328. https://doi.org/10.1093/intimm/dxw027 PMid:27235694 Jiang C., Li J., Zhang W., Zhuang Z., Liu G., Hong W., Li B., Zhang X., and Chao C., 2022, Potential association factors for developing effective peptide-based cancer vaccines, Frontiers in Immunology, 13: 931612. https://doi.org/10.3389/fimmu.2022.931612 PMid:35967400 PMCid:PMC9364268 Kanodia S., and Kast W., 2008, Peptide-based vaccines for cancer: realizing their potential, Expert Review of Vaccines, 7: 1533-1545. https://doi.org/10.1586/14760584.7.10.1533 Khong H., and Overwijk W., 2016, Adjuvants for peptide-based cancer vaccines, Journal for Immunotherapy of Cancer, 4: 56. https://doi.org/10.1186/s40425-016-0160-y Lazoura E., and Apostolopoulos V., 2005, Insights into peptide-based vaccine design for cancer immunotherapy, Current Medicinal Chemistry, 12(13): 1481-1494. https://doi.org/10.2174/0929867054039017 Lim K., Chun N., Gan C., Teo S., Rahman Z., Abraham M., Zain R., Ponniah S., and Cheong S., 2014, Identification of immunogenic MAGED4B peptides for vaccine development in oral cancer immunotherapy, Human Vaccines & Immunotherapeutics, 10: 3214-3223. https://doi.org/10.4161/hv.29226 PMid:25483651 PMCid:PMC4517457 Liu W., Tang H., Li L., Wang X., Yu Z., and Li J., 2021, Peptide-based therapeutic cancer vaccine: current trends in clinical application, Cell Proliferation, 54(5): e13025. https://doi.org/10.1111/cpr.13025 PMid:33754407 PMCid:PMC8088465 Malonis R., Lai J., and Vergnolle O., 2019, Peptide-based vaccines: current progress and future challenges, Chemical Reviews, 120: 3210-3229. https://doi.org/10.1021/acs.chemrev.9b00472 PMid:31804810 PMCid:PMC7094793
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==